Do I need a prescription for Selegiline 1.25mg oral lyophilisates sugar free?

Selegiline 1.25mg oral lyophilisates sugar free is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

Selegiline 1.25mg oral lyophilisates sugar free

Other

1.25mg

Oral

A selective, irreversible inhibitor of Type B monoamine oxidase.

Active ingredients:

Selegiline

Formulation:

Sugar-free

Does not contain sugar — suitable for diabetic patients

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.09.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N04BD01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Selegiline

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Selegiline

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Selegiline

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Selegiline

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

3 branded products available

3 productsShow details

3 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Selegiline on the MHRA register

Zelapar 1.25mg oral lyophilisates

Teva UK Ltd

Discontinued

Zelapar 1.25mg oral lyophilisates

CST Pharma Ltd

Discontinued

Selegiline 1.25mg oral lyophilisates sugar free

Focus Pharmaceuticals Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

5 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Safinamide 50mg tablets

Tablet

50mg

Same therapeutic group

Safinamide 100mg tablets

Tablet

100mg

Same therapeutic group

Rasagiline 2mg/5ml oral solution

Oral solution

2mg/5ml

Same therapeutic group

Rasagiline 2mg/5ml oral suspension

Oral suspension

2mg/5ml

Same therapeutic group

Selegiline 19mg/5ml oral solution

Oral solution

19mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Selegiline

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Selegiline

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42042211000001101

dm+d ID

42042211000001101

VTM (Virtual Therapeutic Moiety)

777509009

VMP (Virtual Medicinal Product)

42042211000001101

BNF code

04090100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N04BD01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

144 found

Half-life

1.2-2 hours

Mechanism

Although the mechanisms for selegiline's beneficial action in the treatment of P…

Food interactions

3 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Rapidly absorbed from the gastrointestinal tract.

Half-life

1.2-2 hours

1.2-2 hours

Protein binding

99.5%

> 99.5%

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Vet approved

Small molecule

About this compound

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Properties:

solid

Avg. mass: 187.29 Da

View FDA drug label

DrugBank indication

Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.

Also known as(93)

(−)-selegiline

L-Deprenalin

Selegilina

Selegiline

Selegilinum

1.4.3.21

1.4.3.4

MAO-B

Dosage forms(12)

Capsule (Oral) — 5 mg/1

Patch (Transdermal) — 12 mg/24h

Patch (Transdermal) — 6 mg/24h

Patch (Transdermal) — 9 mg/24h

Tablet (Oral) — 5.000 mg

Solution (Oral)

Tablet, coated (Oral) — 10 MG

Tablet (Oral) — 10 MG

Molecular properties(18)

Drug interactions(1823)

Known interactions with other medications. Always consult a healthcare professional.

Risperidone

Moderate

DB00734

Selegiline may increase the hypotensive activities of Risperidone.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Selegiline can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Selegiline can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Selegiline can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Selegiline may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Orphenadrine

Moderate

DB01173

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Selegiline.

Check this interaction

Pramipexole

Moderate

DB00413

Selegiline may increase the sedative activities of Pramipexole.

Check this interaction

Rotigotine

Moderate

DB05271

Selegiline may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Selegiline.

Check this interaction

Sodium oxybate

Moderate

DB09072

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Selegiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of hypertension can be increased when Desmopressin is combined with Selegiline.

Check this interaction

Icosapent

Unknown severity

DB00159

The risk or severity of hypertension can be increased when Icosapent is combined with Selegiline.

Check this interaction

Mesalazine

Unknown severity

DB00244

The risk or severity of hypertension can be increased when Mesalazine is combined with Selegiline.

Check this interaction

Tolmetin

Unknown severity

DB00500

The risk or severity of hypertension can be increased when Tolmetin is combined with Selegiline.

Check this interaction

Fenoprofen

Unknown severity

DB00573

The risk or severity of hypertension can be increased when Fenoprofen is combined with Selegiline.

Check this interaction

Sulindac

Unknown severity

DB00605

The risk or severity of hypertension can be increased when Sulindac is combined with Selegiline.

Check this interaction

Sulfasalazine

Unknown severity

DB00795

The risk or severity of hypertension can be increased when Sulfasalazine is combined with Selegiline.

Check this interaction

Carprofen

Unknown severity

DB00821

The risk or severity of hypertension can be increased when Carprofen is combined with Selegiline.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Phenmetrazine is combined with Selegiline.

Check this interaction

Diflunisal

Unknown severity

DB00861

The risk or severity of hypertension can be increased when Diflunisal is combined with Selegiline.

Check this interaction

Meclofenamic acid

Unknown severity

DB00939

The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Selegiline.

Check this interaction

Oxaprozin

Unknown severity

DB00991

The risk or severity of hypertension can be increased when Oxaprozin is combined with Selegiline.

Check this interaction

Balsalazide

Unknown severity

DB01014

The risk or severity of hypertension can be increased when Balsalazide is combined with Selegiline.

Check this interaction

Ephedrine

Unknown severity

DB01364

The risk or severity of hypertension can be increased when Selegiline is combined with Ephedrine.

Check this interaction

Magnesium salicylate

Unknown severity

DB01397

The risk or severity of hypertension can be increased when Selegiline is combined with Magnesium salicylate.

Check this interaction

Salsalate

Unknown severity

DB01399

The risk or severity of hypertension can be increased when Selegiline is combined with Salsalate.

Check this interaction

Choline magnesium trisalicylate

Unknown severity

DB01401

The risk or severity of hypertension can be increased when Selegiline is combined with Choline magnesium trisalicylate.

Check this interaction

Antrafenine

Unknown severity

DB01419

The risk or severity of hypertension can be increased when Selegiline is combined with Antrafenine.

Check this interaction

Tiaprofenic acid

Unknown severity

DB01600

The risk or severity of hypertension can be increased when Selegiline is combined with Tiaprofenic acid.

Check this interaction

Epicaptopril

Unknown severity

DB02032

The risk or severity of hypertension can be increased when Selegiline is combined with Epicaptopril.

Check this interaction

Taxifolin

Unknown severity

DB02224

The risk or severity of hypertension can be increased when Selegiline is combined with Taxifolin.

Check this interaction

Oxyphenbutazone

Unknown severity

DB03585

The risk or severity of hypertension can be increased when Selegiline is combined with Oxyphenbutazone.

Check this interaction

1-benzylimidazole

Unknown severity

DB04581

The risk or severity of hypertension can be increased when Selegiline is combined with 1-benzylimidazole.

Check this interaction

Benoxaprofen

Unknown severity

DB04812

The risk or severity of hypertension can be increased when Selegiline is combined with Benoxaprofen.

Check this interaction

Cimicoxib

Unknown severity

DB05095

The risk or severity of hypertension can be increased when Selegiline is combined with Cimicoxib.

Check this interaction

Amibegron

Unknown severity

DB05395

The risk or severity of hypertension can be increased when Selegiline is combined with Amibegron.

Check this interaction

Showing 50 of 1823 interactions

Food & lifestyle interactions

Advice

Avoid tyramine-containing foods and supplements. Consuming foods containing tyramine such as yogurt, aged cheese, ripe bananas, wine, and sourdough bread may increase the risk of having an uncontrolled hypertensive reaction.

Advice

Take before a meal. Take selegiline oral disintegrating tablets before breakfast and at least 5 minutes before or after any food or drink. Taking selegiline with food reduces the AUC by approximately 60%.

Take With Food

Take with food. Take selegiline capsules or tablets with breakfast and lunch. Food can increase the exposure to selegiline by 3-4 fold.

Toxicity & overdose

LD₅₀=63 mg/kg (rats, IV)

How it works

Mechanism of action

Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.

Pharmacodynamics

Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO-B. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Rapidly absorbed from the gastrointestinal tract.

Half-life

1.2-2 hours

Protein binding

> 99.5%

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Amine oxidase [flavin-containing] B

BE0002196

MAOB

inhibitor

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Substance-P receptor

BE0000384

TACR1

antagonist

Specific functionsubstance P receptor activity

Cellular location

Cell membrane

General function & pharmacology

This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K

Amine oxidase [flavin-containing] A

BE0002198

MAOA

inhibitor

Specific functionflavin adenine dinucleotide binding

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:18391214 PMID:20493079 PMID:24169519 PMID:8316221

Preferentially oxidizes serotonin .
PMID:20493079 PMID:24169519
Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity)

Metabolizing enzymes(8)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2B6Cytochrome P450 2B6

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

CYP2A6Cytochrome P450 2A6

substrate

inhibitor

CYP1A2Cytochrome P450 1A2

substrate

inhibitor

CYP2C19Cytochrome P450 2C19

substrate

CYP2C8Cytochrome P450 2C8

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Scientific references(7)

Engberg G., Elebring T., Nissbrandt H.

Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons..

The Journal of Pharmacology and Experimental Therapeutics

1991259(2):841-847. doi: 10.1016/s0022-3565(25)20337-8

PMID: 1658311 DOI: 10.1016/s0022-3565(25)20337-8

Macleod A.D., Counsell C.E., Ives N., Stowe R.

Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews. 2004. doi: 10.

1002/14651858

cd004898

PMID: 16034956 DOI: 10.1002/14651858.cd004898

Magyar K., Tothfalusi L.

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites*.

Clinical Pharmacology and Therapeutics

199456:742-749. doi: 10.1038/clpt.1994.204

PMID: 6441926 DOI: 10.1038/clpt.1994.204

Heinonen E.H., Anttila M.I., Lammintausta R.A.

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites*.

Clinical Pharmacology and Therapeutics

199456:742-749. doi: 10.1038/clpt.1994.204

PMID: 7995016 DOI: 10.1038/clpt.1994.204

Deleu D., Northway M.G., Hanssens Y.

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson??s Disease.

Clinical Pharmacokinetics

200241(4):261-309. doi: 10.2165/00003088-200241040-00003

PMID: 11978145 DOI: 10.2165/00003088-200241040-00003

Culpepper L., Kovalick L.J.

A Review of the Literature on the Selegiline Transdermal System.

The Primary Care Companion to The Journal of Clinical Psychiatry

200810(01):25-30. doi: 10.4088/pcc.v10n0105

PMID: 18311418 DOI: 10.4088/pcc.v10n0105

Lee K.C., Chen J.J.

Selegiline Transdermal System.

Drugs

200767(2):257-265. doi: 10.2165/00003495-200767020-00006

PMID: 19300583 DOI: 10.2165/00003495-200767020-00006

ATC classification(1 code)

ATC N04BD01

Affected organisms(1)

Humans and other mammals

International brands(2)

Salt forms(1)

Selegiline hydrochloride(DBSALT000260)

Experimental properties(2)

External resources(2)

RxList Drugs.com

Commercial products(44)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Selegiline

DB01037

CAS number

14611-51-9

UNII (FDA)

2K1V7GP655

InChI Key (molecular fingerprint)

MEZLKOACVSPNER-GFCCVEGCSA-N

Additional database identifiers

Drugs Product Database (DPD)

1294

Drugs Product Database (DPD)

11337

ChEBI

9086

PubChem Compound

26757

PubChem Substance

46507655

KEGG Compound

C07245

KEGG Drug

D03731

ChemSpider

24930

BindingDB

15579

PharmGKB

PA451316

Therapeutic Targets Database

DAP000579

Wikipedia

Selegiline

ChEMBL

CHEMBL972

ZINC

ZINC000019632633

RxCUI

9639

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11526

GenAtlas

TACR1

GeneCards

TACR1

GenBank Gene Database

S62045

GenBank Protein Database

8176544

IUPHAR

360

Guide to Pharmacology

360

UniProtKB

P25103

UniProt Accession

NK1R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

International reference pricing

16 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $1.33/tablet

To $627.10/box

Apo-Selegiline 5 mg Tablet

$1.33/tablet

Mylan-Selegiline 5 mg Tablet

$1.33/tablet

Novo-Selegiline 5 mg Tablet

$1.33/tablet

Nu-Selegiline 5 mg Tablet

$1.33/tablet

Pms-Selegiline 5 mg Tablet

$1.33/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 5 expired

7150881

United States

Approved 19 Dec 2006 · Expires 12 Jun 2018

Expired

7070808

United States

Approved 4 Jul 2006 · Expires 10 May 2018

Expired

7638140

United States

Approved 29 Dec 2009 · Expires 10 May 2018

Expired

6423342

United States

Approved 23 Jul 2002 · Expires 1 Mar 2016

Expired

5648093

United States

Approved 15 Jul 1997 · Expires 15 Jul 2014

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Selegiline 1.25mg oral lyophilisates sugar free

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science
12

Chemical identifiers

Selegiline

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Selegiline 1.25mg oral lyophilisates sugar free

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Selegiline

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
12